Pin your most used calculators here by clicking the star in the dropdown.
BCLC Staging System (2022 Update)
Clinical Context & Background
The BCLC system (2022 update) is the standard staging classification for Hepatocellular Carcinoma (HCC). It links staging with treatment indications and prognosis. Updates in 2022 acknowledge the role of systemic therapy for select intermediate-stage (B) patients and establish immunotherapy (Atezolizumab + Bevacizumab) as the standard for advanced stages.
Formula Logic
Classification based on Tumor Burden, Liver Function (Child-Pugh), and Performance Status (ECOG).Reference Data
| BCLC Stage | Classification | Treatment Strategy (2022) |
|---|---|---|
| Stage 0 | Very Early | Ablation (Resection in select cases) |
| Stage A | Early | Resection / Transplant / Ablation |
| Stage B | Intermediate | TACE (or Systemic if diffuse/high burden) |
| Stage C | Advanced | Systemic Therapy (Atezo/Bev) |
| Stage D | Terminal | Best Supportive Care |
Related Tools
Evidence-based oncology decision support. Verify with clinical guidelines.